Intracellular lactate signaling cascade in atrial remodeling of mitral valvular patients with atrial fibrillation

Table 1 Clinical characteristics of study population

Parameters	SR	PaAF	PeAF
Sex, M/F (n)	15/15	15/15	15/15
Age (years)	48.4±11.2	49.1.±10.1	48.7±10.8
Body mass index (kg/m ² )	23.2±2.8	22.9±2.4	22.2±3.1
Heart rate (beats/min)	74±9	77±11	78±15
Mean artery pressure (mm Hg)	84.6±7.2	86.6±9.4	83.2±10.2
C-reactive protein (mg/L)	2.86±1.02	4.32±0.94*	5.04±1.21* ^, **
Duration of valvular disease (years)	4.9±4.8	6.9±5.7	12.5±7.2* ^, **
NYHA class I/II/III/IV (n)	4/9/14/3	3/7/15/5	2/4/17/7
Echocardiographic parameters
LVDd (mm)	48.6±7.4	50.4±6.8	49.2±8.1
LVDs (mm)	31.8±4.7	32.3±5.2	31.1±4.9
EF (%)	63.6±3.9	62.8±4.4	63.4±4.1
LAD (mm)	41.7±6.4	52.4±8.2*	59.9±9.4* ^, **
RAD (mm)	37.7±4.1	42.5±4.6*	46.3±5.7* ^, **
PASP (mm Hg)	34.2±7.7	44.1±11.3*	51.2±14.9* ^, **
Left atrial thrombus (n)	0	3	8* ^, **
Preoperative length of stay (days)	9.6±4.2	12.2±5.6*	15.8±6.8* ^, **
Cause of mitral valve disease (n)
Rheumatic/degenerative	22/8	24/6	28/2* ^, **
Preoperative drug (n)
Digitalis	30	30	30
Calcium-channel blocker	7	5	8
Beta-blocker	3	4	6
ACE-I	5	7	10

Values are presented as mean±SD or number of patients.
ACE-I angiotensin-converting enzyme inhibitor, EF ejection fraction, LAD left atrial diameter, LVDd left ventricular end-diastolic diameter, LVDs left ventricular end-systolic diameter, NYHA New York Heart Association, PASP pulmonary artery systolic pressure, RAD right atrial diameter.
* p<0.05, reference group is the SR group.
** p<0.05, reference group is the PaAF group.

ISSN: 1749-8090